Literature DB >> 15214551

[Neonatal forms of congenital long QT syndrome].

J M Lupoglazoff1, I Denjoy, E Villain, V Fressart, I Legall-Petit, A Bozio, M Berthet, N Benammar, B Hainque, P Guicheney.   

Abstract

UNLABELLED: The neonatal congenital long QT syndrome (LQTS) is rare and of bad prognosis due to the presence of severe ventricular arrhythmia and conduction abnormalities.
METHODS: we included 24 propositus newborns from our population with LQTS. Genetic study was possible in 19 cases.
RESULTS: the diagnosis of LQTS was made according to a QT prolongation associated with a sinusal neonatal bradycardia (n=9) or a 2/1 AV block (n=15). The onset presentation consisted of syncope (n=2), torsades de pointes (n=7), cardiovascular collapse (n=5), cardiac arrest (n=1). The mean QTc was at 550+60 ms. During the neonatal period the treatment consisted of beta-blocking agents in all cases, associated with a definitive pacemaker implantation in 10 cases with 2/1 AV block. Three newborns with a 2/1 AV block died during the first month of life (one case due to a septecemia after implantation of a pacemaker, and two who were waiting for that implantation). All survivors remained asymptomatic during a follow-up period of 7 years. In all cases with a 2/1 AV block we identified mutations in HERG (n=8). Newborns with isolated sinusal bradycardia presented all a mutation in KCNQ1 (n=9).
CONCLUSION: the LTQS with 2/1 AV block is preferably associated with mutation in HERO with a bad initial prognosis.

Entities:  

Mesh:

Year:  2004        PMID: 15214551

Source DB:  PubMed          Journal:  Arch Mal Coeur Vaiss        ISSN: 0003-9683


  2 in total

1.  Survival of a Newborn with 2:1 Atrioventricular Block, Long QT Syndrome, and Torsades de Pointes.

Authors:  Shubho Sarkar; Michael Brumund; Rani Darling; Christopher S Snyder
Journal:  Ochsner J       Date:  2007

Review 2.  Perinatal arrhythmias: diagnosis and management.

Authors:  Janette F Strasburger; Bageshree Cheulkar; Heather J Wichman
Journal:  Clin Perinatol       Date:  2007-12       Impact factor: 3.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.